Evidence map›Paper›PMID 24345481›Full record

ArticleBioorganic & medicinal chemistry2014

Investigation of fluorinated and bifunctionalized 3-phenylchroman-4-one (isoflavanone) aromatase inhibitors.

Erica Amato, Tony Bankemper, Rebecca Kidney, Thuy Do, Alma Onate, Fathima Shazna Thowfeik, Edward J Merino, Stefan Paula, Lili Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Micronutrient Status and Breast Cancer: A Narrative Review.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Chemoprevention of Breast Cancer by Dietary Polyphenols.Molecules (Basel, Switzerland) · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Erica AmatoDepartment of Chemistry, Northern Kentucky University, Nunn Drive, Highland Heights, KY 41099, United States.
Tony BankemperDepartment of Chemistry, Northern Kentucky University, Nunn Drive, Highland Heights, KY 41099, United States.
Rebecca KidneyDepartment of Chemistry, Northern Kentucky University, Nunn Drive, Highland Heights, KY 41099, United States.
Thuy DoDepartment of Chemistry, Northern Kentucky University, Nunn Drive, Highland Heights, KY 41099, United States.
Alma OnateDepartment of Chemistry, Northern Kentucky University, Nunn Drive, Highland Heights, KY 41099, United States.
Fathima Shazna ThowfeikDepartment of Chemistry, University of Cincinnati, Cincinnati, OH 45221, United States.
Edward J MerinoDepartment of Chemistry, University of Cincinnati, Cincinnati, OH 45221, United States.
Stefan PaulaDepartment of Chemistry, Northern Kentucky University, Nunn Drive, Highland Heights, KY 41099, United States.
Lili MaDepartment of Chemistry, Northern Kentucky University, Nunn Drive, Highland Heights, KY 41099, United States. Electronic address: mal1@nku.edu.

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ERIC C ROUCHKA · 2012 to 2026
$60.1M
LCenter for Clinical and Translational Science and TrainingUL1TR001425 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E., KISSELA, BRETT M · 2015 to 2024
$37.5M
Conferring in vivo metabolic resistance to a highly selective anti-AML agentR21CA185370 · NCI · UNIVERSITY OF CINCINNATI · PI MERINO, EDWARD J · 2014 to 2015
$370k
NCATS NIH HHS UL1 TR001425NCI NIH HHS R21 CA185370NIGMS NIH HHS P20 GM103436NIGMS NIH HHS P20GM103436
6 · The paper itself

Abstract

Fluorinated isoflavanones and bifunctionalized isoflavanones were synthesized through a one-step gold(I)-catalyzed annulation reaction. These compounds were evaluated for their in vitro inhibitory activities against aromatase in a fluorescence-based enzymatic assay. Selected compounds were tested for their anti-proliferative effects on human breast cancer cell line MCF-7. Compounds 6-methoxy-3-(pyridin-3-yl)chroman-4-one (3c) and 6-fluoro-3-(pyridin-3-yl)chroman-4-one (3e) were identified as the most potent aromatase inhibitors with IC₅₀ values of 2.5 μM and 0.8 μM. Therefore, these compounds have great potential for the development of pharmaceutical agents against breast cancer.

Indexed as

Aromatase InhibitorsBreast NeoplasmsCell Line, TumorFemaleHumansIsoflavonesAromatase InhibitorsisoflavanoneIsoflavonesAIsArg 115arginine 115aromatase inhibitorsAromatase inhibitorsAsp 309aspartic acid 309Breast cancerCYP19cytochrome P450 aromataseEstrogenFluorineFunctional groupshigh performance liquid chromatographyHPLCIle 133Isoflavanonesisoleucine 133Leu 477leucine 477mass spectrometryMSNMRnon-steroidal aromatase inhibitorsNSAIsnuclear magnetic resonancePhe 221phenylalanine 221selective estrogen receptor modulatorsSERMsThr 310threonine 310Trp 224tryptophan 224Val 370valine 370

Identifiers

PMID24345481
PMCPMC3933948

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.